Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 913-915

  Abenavoli, Ludovico ^a   Milic, Natasa ^b   Masarone, Mario ^c   Persico, Marcello ^d  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; ECHOGRAPHY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; SEROLOGY;

HELICOBACTER PYLORI;

ALANINE TRANSAMINASE; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; CLARITHROMYCIN; CYTOKINES; FATTY LIVER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INSULIN; INSULIN RESISTANCE; ITALY; MALE; METABOLOME; MIDDLE AGED;

EID: 84886794224     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.011     Document Type: Article

References (15)

1. Loria P., Adinolfi L.E., Bellentani S., et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010, 42(4):272-282.
2. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment Pharmacol Ther 2012, 36(9):815-823.
3. Bellentani S., Scaglioni F., Marino M., et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010, 28(1):155-161.
4. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
5. Petta S., Muratore C., Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009, 41(9):615-625.
6. Scaldaferri F., Pizzoferrato M., Gerardi V., et al. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012, 46:S12-S17. Suppl.
7. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
8. Abenavoli L., Milic N., De Lorenzo A., et al. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013, 43(1):65-67.
9. Tonkic A., Tonkic M., Lehours P., et al. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012, (Suppl. 1):1-8.
10. Polyzos S.A., Kountouras J., Papatheodorou A., et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013, 62(1):121-126.
11. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
12. Pellicano R., Menard A., Rizzetto M., et al. Helicobacter species and liver diseases: association or causation?. Lancet Infect Dis 2008, 8:254-260.
13. Abenavoli L., Arena V., Giancotti F., et al. Celiac disease, primary biliary cirrhosis and Helicobacter pylori infection: one link for three diseases. Int J Immunopathol Pharmacol 2010, 23(4):1261-1265.
14. Polyzos S.A., Kountouras J., Zavos C., et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011, 16:79-88.
15. Garinis G.A., Fruci B., Mazza A., et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010, 34(8):1255-1264.